Resorufin: a lead for a new protein kinase CK2 inhibitor
- PMID: 19177021
- DOI: 10.1097/CAD.0b013e328326472e
Resorufin: a lead for a new protein kinase CK2 inhibitor
Abstract
Screening a natural compound library led to the identification of resorufin as a highly selective and potent inhibitor of protein kinase CK2. Out of 52 kinases tested, only CK2 was inhibited, in contrast to emodin, a structurally related, known CK2 inhibitor that, in addition to CK2, inhibited ten other kinases by 90%. The IC50 values determined for the CK2 holoenzymes were 1.5 mol/l and for the free catalytic subunits ca. 4 mol/l. Altogether four cell lines were subjected to resorufin and emodin treatment. In the case of the three prostate carcinoma cell lines (PC-3, DU-145, LNCaP), 24 h treatment with 40 mol/l resorufin led to 15-20% dead cells; however, no caspase-mediated apoptosis was observed. In the case of the colorectal carcinoma HCT116 cell line, a similar picture was obtained, yet, when resorufin was administered to cells treated with doxorubicin, apoptosis was strongly induced within 24 h. Endogenous protein kinase CK2 was inhibited by resorufin by ca. 80% in the three prostate cell lines. In the case of the HCT116 cells, the inhibition was only 40% supporting the notion of cell line-specific selectivity. Moreover, we analysed the effect of resorufin and emodin on selected signalling molecules in the cell lines under investigation.
Similar articles
-
p53 is dispensable for the induction of apoptosis after inhibition of protein kinase CK2.Prostate. 2010 Feb 1;70(2):126-34. doi: 10.1002/pros.21044. Prostate. 2010. PMID: 19760628
-
Inhibition of protein kinase CK2 leads to a modulation of androgen receptor dependent transcription in prostate cancer cells.Prostate. 2007 Feb 1;67(2):125-34. doi: 10.1002/pros.20471. Prostate. 2007. PMID: 17044081
-
Emodin negatively affects the phosphoinositide 3-kinase/AKT signalling pathway: a study on its mechanism of action.Int J Biochem Cell Biol. 2007;39(1):227-37. doi: 10.1016/j.biocel.2006.08.006. Epub 2006 Aug 30. Int J Biochem Cell Biol. 2007. PMID: 17018259
-
CK2 signaling in androgen-dependent and -independent prostate cancer.J Cell Biochem. 2006 Oct 1;99(2):382-91. doi: 10.1002/jcb.20847. J Cell Biochem. 2006. PMID: 16598768 Review.
-
New protein kinase CK2 inhibitors: jumping out of the catalytic box.Chem Biol. 2009 Feb 27;16(2):112-20. doi: 10.1016/j.chembiol.2009.01.004. Chem Biol. 2009. PMID: 19246001 Review.
Cited by
-
Identification of a novel potent, selective and cell permeable inhibitor of protein kinase CK2 from the NIH/NCI Diversity Set Library.Mol Cell Biochem. 2015 Aug;406(1-2):151-61. doi: 10.1007/s11010-015-2433-z. Epub 2015 May 12. Mol Cell Biochem. 2015. PMID: 25963666
-
Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer.Mol Cell Biochem. 2011 Oct;356(1-2):37-43. doi: 10.1007/s11010-011-0956-5. Epub 2011 Jul 14. Mol Cell Biochem. 2011. PMID: 21755459
-
Inhibition of protein kinase CK2 expression and activity blocks tumor cell growth.Mol Cell Biochem. 2010 Jan;333(1-2):159-67. doi: 10.1007/s11010-009-0216-0. Epub 2009 Jul 21. Mol Cell Biochem. 2010. PMID: 19629644
-
[Protein kinase CK2 and human malignant tumors].Zhongguo Fei Ai Za Zhi. 2012 Jul;15(7):439-45. doi: 10.3779/j.issn.1009-3419.2012.07.09. Zhongguo Fei Ai Za Zhi. 2012. PMID: 22814265 Free PMC article. Review. Chinese. No abstract available.
-
Chemical Genetic Validation of CSNK2 Substrates Using an Inhibitor-Resistant Mutant in Combination with Triple SILAC Quantitative Phosphoproteomics.Front Mol Biosci. 2022 Jun 9;9:909711. doi: 10.3389/fmolb.2022.909711. eCollection 2022. Front Mol Biosci. 2022. PMID: 35755813 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
